{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-023589","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.946710+00:00","generated_at":"2026-06-04T14:45:44.541355+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protara CMO Jathin Bandari resigns effective April 11; interim oversight assigned","bullets":["CMO Jathin Bandari resigns effective April 11, 2024 to explore academic opportunities; consulting through July 11.","Severance includes $365,386 lump sum (9 months salary), $164,424 bonus, COBRA for 9 months, and pro-rata vesting of 11,993 options + 5,886 RSUs.","Interim oversight: Jacqueline Zummo (SVP & Chief Scientific Ops Officer) leads medical staff, advised by board member Richard Levy, M.D.","Company plans to search for a new Chief Medical Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-023589","json":"https://secwatch.observer/filing/0001213900-24-023589.json","markdown":"https://secwatch.observer/filing/0001213900-24-023589.md","text":"https://secwatch.observer/filing/0001213900-24-023589.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024023589/0001213900-24-023589-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024023589/ea0202028-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T14:45:44.541355+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9148ac1aa6","claim":"Jathin Bandari resigned as Chief Medical Officer at Protara Therapeutics, Inc..","evidence_excerpt":"On March 18, 2024, Protara Therapeutics, Inc. (the “Company”) announced that Jathin Bandari, M.D., Chief Medical Officer of the Company, will be resigning from the Company to explore other opportunities, including devoting more time to academic work, effective as of April 11, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024023589/0001213900-24-023589-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}